PER

14.3%

0.8¢

PERCHERON THERAPEUTICS LIMITED

Market Cap $8.699M Add to my watchlist

Healthcare Biotechnology

Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a... Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) receives Indonesian approval for Phase 3 diabetic foot infection trial.

Latest Threads

Tag

Subject

PER

Juststocks interview

11:29

10K

11:29

Last post nottawombat

10K

PER

where to from here

2 3

10:12

142

43K

10:12

Last post Atomboi

142

43K

PER

Wrong trial participants

27/12/24

906

27/12/24

Last post ammie

906

PER

Ann: Change of Director's Interest Notice - Dr James Garner

27/12/24

1.6K

27/12/24

Last post dontfollowme

1.6K

PER

Ann: Topline Six-Month Results From Phase IIb Study of Avicursen

2 3 4

23/12/24

181

65K

23/12/24

Last post arjay

181

65K

PER

Ann: Change in substantial holding

2 3

23/12/24

127

36K

23/12/24

Last post DimDim

127

36K

PER

Ann: Clinical Trial Update

4 5 6

20/12/24

353

101K

20/12/24

Last post koenermann

353

101K

PER

Ann: Change of Director's Interest Notice-Dr Charmaine Gittleson

20/12/24

882

20/12/24

Last post Bluesky24

882

See All Discussions

Timeline

Change of Director's Interest Notice - Dr James Garner
27 Dec 08:27	Share

Change of Director's Interest Notice-Dr Charmaine Gittleson
20 Dec 19:33	Share

Notification of cessation of securities - PER
20 Dec 19:25	Share

Change in substantial holding
19 Dec 16:48	Share

Topline Six-Month Results From Phase IIb Study of Avicursen
18 Dec 09:25	Share

Trading Halt
16 Dec 09:19	Share

Reorganisation of US Quoted Securities
03 Dec 09:31	Share

Clinical Trial Update
02 Dec 09:03	Share

Resignation of Joint Company Secretary
02 Dec 08:55	Share

Notification regarding unquoted securities - PER
29 Nov 17:05	Share

Change of Director's Interest Notice - Dr James Garner
28 Nov 08:44	Share

Notice under S708A
27 Nov 08:54	Share

Application for quotation of securities - PER
26 Nov 09:32	Share

Change of Director's Interest Notice - Dr Ben Gil Price
25 Nov 16:42	Share

Change of Director's Interest Notice Dr James Garner
25 Nov 16:40	Share

Notification regarding unquoted securities - PER
25 Nov 16:37	Share

Proposed issue of securities - PER
21 Nov 15:03	Share

Proposed issue of securities - PER
21 Nov 14:56	Share

Results of the Annual General Meeting
21 Nov 14:45	Share

Annual General Meeting Management Presentation
21 Nov 09:48	Share

Annual General Meeting - Chair's Address
21 Nov 09:45	Share

Withdrawal of Resolutions from the Annual General Meeting
21 Nov 09:43	Share

Change in substantial holding
15 Nov 16:39	Share

Change of Director's Interest Notice - Dr James Garner
14 Nov 10:08	Share

Application for quotation of securities - PER
14 Nov 10:00	Share

Results of Share Purchase Plan
13 Nov 08:39	Share

Quarterly Activities Report and Appendix 4C
31 Oct 08:33	Share

Percheron launches post-trial access program
28 Oct 09:34	Share

Share Purchase Plan Offer Booklet
28 Oct 08:27	Share

Notice under S708A
25 Oct 08:23	Share

View More

(20min delay)
Last 0.8¢		Change 0.001(14.3%)		Mkt cap ! $8.699M

Open	High	Low	Value	Volume
0.7¢	0.8¢	0.7¢	$161.1K	20.50M

Buyers (Bids)

No.	Vol.	Price($)
6	2232619	0.8¢

Sellers (Offers)

Price($)	Vol.	No.
0.9¢	7815678	12

View Market Depth

No.	Vol.	Price($)
6	2232619	0.008
27	14706576	0.007
42	17517358	0.006
31	23734983	0.005
12	6926199	0.004

Price($)	Vol.	No.
0.009	7815678	12
0.010	17298678	12
0.011	1011901	4
0.012	6254164	7
0.013	2371425	5

Last trade - 16.10pm 27/12/2024 (20 minute delay)

PER (ASX) Chart

PERCHERON THERAPEUTICS LIMITED

Latest Threads

Timeline

Featured News

Latest Articles

Percheron Therapeutics lays out expected timeline for avicursen trial data

Percheron expects to deliver topline data from its Duchenne muscular dystrophy (DMD) trial using avicursen from December 16.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News